Do you want to be part of an organisation that truly makes a difference in your community? Sweet Louise is looking for a motivated, committed, compassionate individual to join our team in Auckland as part of the coordinator network.
Please note the Members' Days have now been delayed to February 2022 due to the ongoing COVID-19 lockdown and restrictions.
Sweet Louise members are warmly invited to Members' Day!
When: Two dates to be advised in February in Christchurch and Auckland
This year Sweet Louise are thrilled to be announcing two centres for their members days, Auckland and Christchurch, thanks to the generous support of their partners.
The day will be filled with practical workshops and professional talks - all created in the hope of helping and honouring YOU while you navigate your own journey with advanced breast cancer. Both venues offer a range of opportunities for you to share experiences and learn through talks and discussions and practical workshops themed around wellbeing.
A full programme will be provided to all who register.
Spaces are limited to 100 in Auckland and 50 in Christchurch so register now through your Sweet Louise Support Co-ordinator to avoid disappointment.
Rotorua Breast Cancer Trust (RBCT) AGM
The team at RBCT would love to see as many people as possible at their Annual General Meeting taking place at the Rotorua Library. If you'd like to become more involved in the Trust or perhaps join the Trust please go along. The AGM will be followed by tea, coffee and light refreshments.
When: Tuesday 29 June, 6:30 pm
Where: Rotorua Library
For more information visit www.rotoruabreastcancertrust.co.nz or email info@rbct.co.nz
Step back in time and join the Waikato Breast Cancer Research Trust for a 1920s inspired night of glitz, glam and all that jazz in celebration of 21 years of existence.
When: 19 August, 6:30 pm
Where: Gallagher Academy of Performing Arts, Knighton Rd, University of Waikato, Hamilton
Tickets: $150
To buy tickets visit: 21st Cocktail Event | Waikato Breast Cancer Research Trust (infoodle.com)
Click here for more information about the Waikato Breast Cancer Research Trust.
This clinical trial is investigating the efficacy and safety of GDC-9545 combined with palbociclib compared with Letrozole combined with palbociclib in patients with oestrogen receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
Who is the trial for? Women or men with confirmed hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer. Patients must have progressed greater than 12 months after completing adjuvant treatment with endocrine therapy. They should also have no serious medical conditions and a life expectancy of greater than six months. It does include patients with bone-only disease. Auckland City Hospital and Waikato Hospital are New Zealand sites for this trial.
View this link for full trial information.
Please consult with your doctor or medical team if you are interested in participating in this trial.
15 May 2023
This study will evaluate the efficacy and safety of GDC-0077 plus palbociclib and fulvestrant versus a placebo plus palbociclib and fulvestrant in patients with PIK3CA-mutant, hormone receptor positive, HER2-negative, locally advanced or metastatic breast cancer.
Who is the trial for? Women or men with confirmed hormone receptor positive, HER2-negative locally advanced or metastatic breast cancer; confirmed biomarker PIK3CA mutation; they must have progressed during adjuvant treatment or within 12 months of completing endocrine therapy. Patients with bone only disease or history of type 1 or 2 diabetes are excluded.
New Zealand sites for this trial are: Auckland City Hospital, Waikato Hospital, Palmerston North Hospital and Christchurch Hospital. Please ask your doctor or medical team if you are interested in participating in this trial.
More trial information is available here.
15 May 2023
The NeoN trial is coordinated through Breast Cancer Trials (ANZ) and will investigate if using an immunotherapy drug alone prior to the combination of immunotherapy and standard chemotherapy is safe and effective in treating breast cancer before surgery.
Standard treatment of triple negative breast cancer typically consists of surgery, chemotherapy and usually a course of radiotherapy. Often chemotherapy treatment is given prior to breast surgery (neo-adjuvant chemotherapy) as it is effective in reducing the size of the breast cancer while providing useful information about the effectiveness of the treatment being given.
Researchers are working to identify more effective treatment options for triple negative breast cancer patients. The purpose of this study is to see if using the immunotherapy drug (nivolumab) together with standard chemotherapy (paclitaxel and carboplatin) is safe and effective in treating breast cancer before surgery. Immunotherapy drugs developed to block these immune checkpoint signals have shown anti-cancer activity across multiple solid tumours such as melanoma and non-small cell lung cancer. One such immunotherapy drug is 'Nivolumab', which works by blocking PD-1 signalling.
In this study nivolumab was given in combination with paclitaxel and carboplatin to treat triple negative breast cancer. Everyone in the study received standard chemotherapy and also the immune therapy however participants had a 50:50 chance (randomly allocated) of receiving an additional immunotherapy dose prior to chemotherapy ('Lead in') or an additional immunotherapy dose after chemotherapy ('Lead out'). Nivolumab is not an approved treatment for early breast cancer in Australia. The study design will help us understand if the nivolumab 'lead in' dose can effectively activate the body's immune response before the addition of chemotherapy. This may contribute to better outcomes and result in a new standard treatment for triple negative breast cancer patients.
This trial is now closed but you can read more about it here.
15 May 2023
These last few months have been a whirlwind for the P
Breast Cancer Aotearoa Coalition (BCAC) representativ
